13F Filings History of REGENERON PHARMACEUTICALS, INC.

Latest 13F report
Q4 2025 - 06 Feb 2026
Value $
$33,799,428
Signature - Title
Leonard Brooks - Senior Vice President, Treasurer
Location
Tarrytown, NY
Summary
This page shows a list of all the recent 13F filings made by REGENERON PHARMACEUTICALS, INC.. Form 13F is required to be filed within 45 days of the end of a calendar quarter. REGENERON PHARMACEUTICALS, INC. reported 2 stock holdings with total value $33,799,428 as of Q4 2025.

Follow Filing Activity

Follow REGENERON PHARMACEUTICALS, INC. and return when a new 13F portfolio filing appears.

This tracks SEC filing changes for this page using existing product update flows.

Sign up to follow filing activity
Holdings Value

Sponsored

Quick Takeaways

  • REGENERON PHARMACEUTICALS, INC. reports institutional holdings through Form 13F filings.
  • Latest reported quarter: Q4 2025.
  • Latest reported holdings value: $33,799,428.

What Changed

  • Most recent filing was accepted on 06 Feb 2026, 17:06.
  • Reported value moved from $700,444,832 to $33,799,428.

Why This Matters

  • This gives a plain-language read of holdings direction before you open full quarter tables.
  • Use the filing links below to verify the exact SEC source document.

Official SEC Source

Backed by Form 13F

Portfolio holdings and changes are grounded in SEC Form 13F filings.

See Original Filing
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Filing Time
Q4 2025 2 $33,799,428 $0 -$643,352,290 -$643,352,290 NTLA, ACET 13F-HR 06 Feb 2026, 17:06
Q3 2025 4 $700,444,832 $0 -$1,391,776,752 -$1,391,776,752 ALNY, NTLA, ADVM, ACET 13F-HR 07 Nov 2025, 16:55
Q2 2025 4 $1,485,002,709 $0 -$6,301,325 -$6,301,325 ALNY, NTLA, ACET, ADVM 13F-HR 01 Aug 2025, 16:09
Q1 2025 6 $1,234,240,208 $0 $0 $0 ALNY, NTLA, TSVT, ADVM, ACET 13F-HR 02 May 2025, 16:15
Q4 2024 6 $1,094,639,843 $0 $0 $0 ALNY, NTLA, TSVT, ACET, ADVM 13F-HR 07 Feb 2025, 16:36

Sponsored